Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 2/20 | 0.52 |
| ▸ | OTC | P00480 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | ARG2 | P78540 | 4/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30033086 | 1.00 | DDAH1 (0.52) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL458808 | 1.00 | DDAH1 (0.52) | DDAH1OTCGSRDPP7DPP8 | |
| Hydrochloric Acid SCHEMBL30096368 | 0.99 | DDAH1 (0.51) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL7194971 | 0.95 | DDAH1 (0.57) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL22281180 | 0.95 | DDAH1 (0.57) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL28297586 | 0.95 | DDAH1 (0.57) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL24185361 | 0.89 | DDAH1 (0.46) | DDAH1OTCGSRSLC1A3SLC1A1 | |
| SCHEMBL31710914 | 0.89 | DDAH1 (0.53) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL30310821 | 0.88 | DDAH1 (0.43) | DDAH1DPP7DPP8ANPEPDPP4 | |
| SCHEMBL24946771 | 0.88 | DDAH1 (0.44) | DDAH1OTCGSRDPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406706-A | Method for regulating and controlling release of target protein by utilizing unnatural amino acid | 武汉大学 | 2024-07-30 | — | — | CN | claimed |
| CN-116601297-A | Modified helicase and application thereof | 北京齐碳科技有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-114599666-A | Pif1-like helicase and application thereof | 北京齐碳科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-113930406-A | Pif1-like helicase and application thereof | 北京齐碳科技有限公司 | 2022-01-14 | — | — | CN | claimed |
| CN-105899678-A | Modified enzymes | 牛津纳米孔技术公司 | 2016-08-24 | — | — | CN | claimed |
| US-12521437-B2 | IL-2 conjugates and methods of use thereof | Synthorx, Inc. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12491254-B2 | Interleukin 10 conjugates and uses thereof | Synthorx, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3876973-B1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | SYNTHORX INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12377131-B2 | Cytokine conjugates for the treatment of autoimmune diseases | Synthorx, Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12344648-B2 | IL-15 conjugates and uses thereof | Synthrox, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20120157660-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157660-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110282029-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110282029-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20090005292-A1 | Novel Peptides that Bind to the Erythropoietin Receptor | AFFYMAX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005292-A1 | Novel Peptides that Bind to the Erythropoietin Receptor | AFFYMAX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080108564-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108564-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491254-B2 | Interleukin 10 conjugates and uses thereof | IL2, CCR10, IL2RA | DDAH1 4049/4885OTC 1143/4885GSR 1704/4885 |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | DDAH1 4047/4885OTC 1738/4885GSR 782/4885 |
| US-20080108564-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | DDAH1 3520/4885OTC 4048/4885GSR 3036/4885 |
| US-20110282029-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | DDAH1 3520/4885OTC 4048/4885GSR 3036/4885 |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | DDAH1 3889/4885OTC 2155/4885GSR 1429/4885 |
| US-12377131-B2 | Cytokine conjugates for the treatment of autoimmune diseases | IL2, IL2RA, IL15 | DDAH1 4047/4885OTC 1738/4885GSR 782/4885 |
| US-20090005292-A1 | Novel Peptides that Bind to the Erythropoietin Receptor | EPOR, PROKR1, EDNRB | DDAH1 3520/4885OTC 4048/4885GSR 3036/4885 |
| US-20120157660-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | DDAH1 3520/4885OTC 4048/4885GSR 3036/4885 |
| US-12344648-B2 | IL-15 conjugates and uses thereof | IL15, IL15RA, IL5 | DDAH1 2678/4885OTC 2039/4885GSR 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.